Journal of Chemotherapy最新文献

{"title":"The crucial relationship between vancomycin minimum inhibitory concentration and therapeutic efficacy against methicillin-resistant coagulase-negative staphylococci.","authors":"Yusuke Niinuma, Keisuke Kagami, Mitsuru Sugawara, Yoh Takekuma","doi":"10.1080/1120009X.2024.2394326","DOIUrl":"10.1080/1120009X.2024.2394326","url":null,"abstract":"<p><p>The area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio was used as an indicator of the clinical efficacy of vancomycin. However, the target AUC/MIC has not been set for methicillin-resistant coagulase-negative staphylococci (MR-CNS), and the effectiveness of vancomycin in strains with high MIC is unknown. Therefore, we aimed to investigate the relationship between the vancomycin MIC and therapeutic efficacy in patients with MR-CNS bacteremia. The primary outcome was the difference in treatment failure rate when the MR-CNS vancomycin MIC was 1 or 2 µg/mL. The treatment failure rate did not significantly differ between the two groups (MIC 1 vs. MIC 2: 27.0% vs. 31.0%; <i>p</i> = 0.779). As a result of multivariate analysis, AUC/MIC_0-24 h ≤230 was extracted as risk factor for treatment failure, suggesting the importance of a sufficient initial loading dose and early blood concentration monitoring to increase AUC/MIC_0-24 h for successful treatment.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"326-333"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway.","authors":"Teng Ren, Hongpei Zhang, Yurou Liu, Juan Wang, Miaomiao Liu, Yanli Chen","doi":"10.1080/1120009X.2025.2522508","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2522508","url":null,"abstract":"<p><p>Chidamide, a histone deacetylase inhibitor with established anti-tumor properties, requires further investigation regarding its specific impact on lung cancer progression. Our results showed that chidamide treatment significantly inhibited proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells while inducing apoptosis. The treatment with chidamide also downregulated methyltransferase 3 (METTL3), the catalytic subunit of the N6-adenosine-methyltransferase complex, in A549 and H1299 cells. Overexpression of METTL3 reversed the inhibitory effects of chidamide on NSCLC cell progression. Furthermore, we found that METTL3 stabilized EPH receptor A7 (EPHA7) expression through an m6A-dependent mechanism. Conversely, overexpression of EPHA7 counteracted the effects of METTL3 silencing or chidamide treatment in both cell lines. <i>In vivo</i>, chidamide treatment reduced EPHA7 protein expression by regulating METTL3, leading to inhibited tumor growth. Collectively, these findings identified the METTL3/EPHA7 axis as a key mediator of chidamide's anti-tumor effects, suggesting chidamide's potential as a novel therapeutic strategy for NSCLC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.","authors":"Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa, Yasuhiro Gon","doi":"10.1080/1120009X.2025.2524914","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2524914","url":null,"abstract":"<p><p>Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact of response on survival differed by the ICI type. We conducted a study on 137 patients who received ICIs (pembrolizumab or atezolizumab) plus chemotherapy for chemotherapy-naïve advanced NSCLC. We analyzed the association between response and survival for each type of ICIs. In the response group, the pembrolizumab-based regimen had significantly more prolonged PFS than the atezolizumab-based regimen (48.1 vs. 8.6 months, P < 0.01). OS was also significantly different between the two groups (Not reached vs. 32.5 months, P = 0.04). Multivariate analysis showed that the pembrolizumab regimen reduced the risk of disease progression by 63% compared to the atezolizumab regimen. The impact of the response on survival differs according to the ICI type.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety analysis of oral <i>isavuconazole</i> therapy of invasive pulmonary aspergillosis.","authors":"Yanli Gu, Rong Zhang, Wei Ding, Bing Sun, Wei Chen, Zili Meng, Liang Chen","doi":"10.1080/1120009X.2025.2523659","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2523659","url":null,"abstract":"<p><p>This retrospective study aimed to explore the efficacy and safety of oral isavuconazole in treating invasive pulmonary aspergillosis (IPA). Among 31 enrolled patients, 21 survived and 10 died by the 42-days follow-up. The mean hospitalization duration was 21.81 ± 8.03 days, with isavuconazole administered for a mean of 25.10 ± 12.87 days. Survivors received isavuconazole for significantly longer period than non-survivors (28.62 vs 17.70 days, <i>P</i> = 0.025). The time to initiation of isavuconazole was significantly shorter in survivors compared to non-survivors (7.86 vs 14.4 days, <i>P</i> = 0.013). Early initiation of treatment was significantly associated with a shorter hospital stay (16.33 vs 25.83 days, <i>P</i> < 0.001). No significant adverse effects were observed in laboratory parameters, and no patients discontinued treatment due to side effects. These findings suggest that early oral administration of isavuconazole may reduce mortality rates and shorten hospitalization duration in patients with IPA. The treatment demonstrated a favourable safety profile, with minimal adverse reactions.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of dostarlimab plus chemotherapy <i>versus</i> pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.","authors":"Tong Liu, Xin Zhang, Bingjie Liu, Yao Yao, Ruihong Yao, Zhiqiang Tong, Xue Teng, Mei Dong, Lu Zhong","doi":"10.1080/1120009X.2025.2524906","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2524906","url":null,"abstract":"<p><p>Lung cancer is one of the most common malignant cancers in most countries, and non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Checkpoint inhibitor immunotherapy is the preferred therapy for metastatic NSCLC patients who do not exhibit EGFR exon 19 deletion or L858R or ALK, RET, or ROS1 rearrangements. A recent clinical study (PERLA, NCT04581824) reports that dostarlimab has comparable effectiveness to pembrolizumab and presents clinical reliability as a first-line treatment for patients with metastatic non-squamous NSCLC. Our study employed a partitioned survival model (PSM) to evaluate the cost-effectiveness of dostarlimab plus chemotherapy compared to pembrolizumab plus chemotherapy as a first-line treatment of metastatic NSCLC from the perspective of healthcare payers in China. We found that when the time horizon was 10 years, dostarlimab plus chemotherapy was not cost-effective at the willingness to pay (WTP) threshold of 287,247 Chinese yuan (CNY)/QALY (35,057 EUR/QALY at an exchange rate of 1 CNY = 0.122 EUR).</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of synthetic lethality-associated subtypes and construction of risk model to predict breast cancer prognosis and immune characteristics.","authors":"Jianhong Tang, Weihong Chen, Weibao Zou, Shujuan Cao","doi":"10.1080/1120009X.2025.2512263","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512263","url":null,"abstract":"<p><p>Synthetic lethality has emerged as a pivotal concept in cancer therapy, offering novel and promising strategies for treatment. In this study, we identified molecular subtypes associated with synthetic lethality in breast cancer and developed a prognostic signature based on synthetic lethality-related genes. Using the TCGA cohort, we screened differentially expressed synthetic lethal genes (DESLGs) and stratified patients into two distinct molecular subtypes based on their expression patterns. Immune profiling and clinical survival analyses revealed significant differences between these subtypes. A six-gene prognostic risk model was constructed using univariate and multivariate Cox regression analyses combined with LASSO regression, and its robustness was validated in independent GEO datasets. Independent prognostic analyses integrating clinical and pathological features were performed, followed by the construction of a nomogram to improve clinical applicability. The immune microenvironment was characterized using ssGSEA, ESTIMATE, and CIBERSORT algorithms, revealing a lower level of immune infiltration and distinct immune checkpoint expression in the high-risk group. In addition, patients in the high-risk group exhibited worse survival outcomes, higher tumor mutation burden, and increased resistance to several therapeutic agents. RT-qPCR analysis confirmed the differential expression of signature genes between breast cancer and normal mammary epithelial cells. These findings suggest that the synthetic lethality-based molecular subtypes and prognostic model offer reliable tools for evaluating clinical outcomes and guiding individualized therapy in breast cancer patients.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-22"},"PeriodicalIF":1.9,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review.","authors":"G Silvi, E Rosi, I Scandagli, A Di Cesare, F Prignano","doi":"10.1080/1120009X.2025.2512264","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512264","url":null,"abstract":"<p><p>We report the case of a 77-year-old man with recurrent oral squamous cell carcinoma who developed erythema multiforme (EM) following his third dose of pembrolizumab (PBZ). The patient presented with a widespread skin rash characterized by erythematous papules and plaques that evolved into targetoid lesions, with no mucosal involvement or systemic symptoms. The treatment with a tapering dose of prednisolone resolved the rash without interrupting PBZ therapy. The report reviews the existing literature on PBZ-induced EM as a rare cutaneous toxicity associated with immune-checkpoint inhibitors (ICIs). Prompt recognition and appropriate management of EM are crucial. The discussion emphasizes the importance of distinguishing it from more severe conditions such as toxic epidermal necrolysis or Stevens-Johnson syndrome. Decisions regarding the continuation of PBZ therapy should be made collaboratively by dermatologists and oncologists, considering the patient's overall health and cancer treatment plan.Key PointsImmune-checkpoint inhibitors like pembrolizumab have revolutionized cancer treatment, though skin toxicities can complicate therapy.EM is a rare side effect of pembrolizumab, occurring in only 0.1% of patients, usually without affecting mucous membranes.Cases of pembrolizumab-induced EM vary in severity but generally respond well to corticosteroids.Quick identification of EM is essential, and treatment continuation should be carefully considered based on cancer type and severity.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.9,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report.","authors":"Sercan Ön","doi":"10.1080/1120009X.2025.2512262","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512262","url":null,"abstract":"<p><p>Gestational trophoblastic neoplasia (GTN) is a rare malignancy that can develop following a hydatidiform mole or a non-molar pregnancy and often presents with metastasis. Although conventional chemotherapy achieves remission in over 90% of metastatic cases some patients develop resistance. I report a 36-year-old woman with metastatic GTN after prolonged uterin bleeding and elevated β-hCG levels. Despite multiple chemotherapy regimens, including cisplatin/etoposide and EMA-CO, the patient did not achieve remission. After the failure of conventional chemotherapy, pembrolizumab, an immune checkpoint inhibitor, was introduced. This treatment resulted in a rapid decrease in β-hCG levels and a complete biochemical response. The treatment was well tolerated, only minor immune-related adverse events. After eight cycles of pembrolizumab, she remained in remission for one year. This case highlights the potential role of immunotherapy in managing chemoresistant metastatic GTN and underscores the need for further studies to establish its effectiveness in such situations.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":1.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells.","authors":"Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang","doi":"10.1080/1120009X.2025.2508614","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2508614","url":null,"abstract":"<p><p>Although cinobufagin has been demonstrated to inhibit the growth of various malignant tumors, its functional role in ovarian cancer remains unclear. In light of this, the present study aims to thoroughly investigate the effects of cinobufagin on ovarian cancer progression and elucidate its underlying molecular mechanisms, thereby providing novel insights into future therapeutic strategies. A2780/DDP, a cisplatin-resistant cell line for ovarian cancer, was treated with gradient doses of cinobufagin. The microRNA-149-3p and AFF4 binding sites were predicted by bioinformatics. In cisplatin-resistant ovarian cancer cells, microRNA-149-3p and AFF4 expression were detected using qRT-PCR, and the binding association between microRNA-149-3p and AFF4 was confirmed by dual-luciferase and RIP assays. Cell viability was assessed using the CCK-8 test, cell proliferation was identified using the EdU assay and colony formation, and cell apoptosis was identified using flow cytometry. The results showed that cinobufagin inhibited the proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. microRNA-149-3p was highly expressed in cisplatin-resistant ovarian cancer cells, while AFF4 was lowly expressed in these cells. Overexpression of microRNA-149-3p promoted the proliferation and inhibited the apoptosis of cisplatin-resistant ovarian cancer cells, which was reversed by the addition of cinobufagin. Overexpression of AFF4 suppressed proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. MicroRNA-149-3p repressed AFF4 expression, and partial attenuation of the effects of AFF4 overexpression on cell phenotype was observed when microRNA-149-3p was overexpressed. In conclusion,cinobufagin regulated microRNA-149-3p/AFF4 axis to inhibit proliferation of ovarian cancer cells and promote cell apoptosis. Targeting the microRNA-149-3p/AFF4 axis with cinobufagin could represent a novel therapeutic strategy for ovarian cancer.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PqsR-specific quorum sensing inhibitors targeting <i>Pseudomonas aeruginosa</i>: current advances and future directions.","authors":"Mandsaurwala Aziz, Kafil Ahmed, Vinothkannan Ravichandran","doi":"10.1080/1120009X.2025.2510093","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2510093","url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa is driven by diverse resistance mechanisms, including quorum sensing (QS) and biofilm formation. QS regulates virulence, antibiotic tolerance, efflux pumps, and biofilm development, enhancing the pathogen's adaptability. Among QS systems, the Pseudomonas quinolone signal regulator (PqsR) plays a central role in controlling virulence and biofilm-associated genes. This review critically examines the PqsR-regulated network and highlights the potential of PqsR inhibitors to reduce pathogenicity. Disrupting QS instead of targeting bacterial viability can enhance antibiotic efficacy, making this combinatorial approach a promising strategy to combat MDR <i>P. aeruginosa</i>.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}